News
27 February, 2026 27 February, 2026 The Transparency Council meeting 10/2026 on 9 March 2026
read more26 February, 2026 Recommendation of the President – Poltixa (apixaban)
read more24 February, 2026 Recommendation of the President – Tript-OH and Levotonine (L-5-hydroxytryptophan)
read more23 February, 2026 Recommendation of the President – Tyrvaya (varenicline)
read more23 February, 2026 The Transparency Council meeting 9/2026 on 2 March 2026
read more20 February, 2026 Publication AWA
read more20 February, 2026 Status of work in February
read more20 February, 2026 Recommendation of the President – Opdivo (nivolumab)
read more20 February, 2026 Recommendation of the President – Alyftrek (deutiwakaftor, tezakaftor, wanzakaftor)
read more20 February, 2026 Recommendation of the President – parathyroid biopsy
read more19 February, 2026 Webinar for patient organizations – “AOTMiT and patient organizations – how it works in practice”
read more17 February, 2026 The Transparency Council meeting 8/2026 on 23 February 2026
read more16 February, 2026 Guaranteed benefits covering diagnostic lump sums under oncology drug programs
read more13 February, 2026 Publication AWA
read more13 February, 2026 Status of work in February
read more13 February, 2026 Recommendation of the President – Keytruda (pembrolizumab)
read more10 February, 2026 Recommendation of the President – Iwilfin (eflornithine)
read more10 February, 2026 Sign the document in the mObywatel app
read more10 February, 2026 Recommendation of the President – Brukinsa (zanubrutinib)
read more10 February, 2026 Recommendation of the President – Spevigo (spesolimab)
read more10 February, 2026 Recommendation of the President – Spevigo (spesolimab)
read more10 February, 2026 Recommendation of the President – comprehensive outpatient and day healthcare services, including diagnosis and treatment, provided as part of a forensic psychiatry
read more09 February, 2026 Recommendation of the President – Diaflix (dapagliflozin)
read more